Cargando…
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study
SIMPLE SUMMARY: The prognostic relevance of a patient achieving complete response to hydroxyurea, the predictors of response, and patients’ triggers for switching to ruxolitinib are uncertain. A retrospective, real-world analysis was performed on 563 polycythemia vera patients treated with hydroxyur...
Autores principales: | Palandri, Francesca, Rossi, Elena, Auteri, Giuseppe, Breccia, Massimo, Paglia, Simona, Benevolo, Giulia, Elli, Elena M., Cavazzini, Francesco, Binotto, Gianni, Tieghi, Alessia, Tiribelli, Mario, Heidel, Florian H., Bonifacio, Massimiliano, Pugliese, Novella, Caocci, Giovanni, Crugnola, Monica, Mendicino, Francesco, D’Addio, Alessandra, Tomassetti, Simona, Martino, Bruno, Polverelli, Nicola, Ceglie, Sara, Mazzoni, Camilla, Mullai, Rikard, Ripamonti, Alessia, Garibaldi, Bruno, Pane, Fabrizio, Cuneo, Antonio, Krampera, Mauro, Semenzato, Gianpietro, Lemoli, Roberto M., Vianelli, Nicola, Palumbo, Giuseppe A., Andriani, Alessandro, Cavo, Michele, Latagliata, Roberto, De Stefano, Valerio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377857/ https://www.ncbi.nlm.nih.gov/pubmed/37509367 http://dx.doi.org/10.3390/cancers15143706 |
Ejemplares similares
-
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
por: Palandri, Francesca, et al.
Publicado: (2023) -
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2021) -
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic‐phase myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2022) -
P1011: PREDICTORS OF COVID-19 DISEASE AND SURVIVAL TO COVID-19 IN MPN PATIENTS TREATED WITH RUXOLITINIB
por: Palandri, F., et al.
Publicado: (2022) -
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2023)